Fallopian tube carcinoma

This phase II trial tests whether an IGFBP-2 vaccine, given after one dose of carboplatin, can stop ovarian cancer from growing in patients whose recurrence is detected only through a blood test. The vaccine helps the immune system target cancer cells, while carboplatin primes th…

This Phase 3 trial tests whether a targeted therapy called sacituzumab tirumotecan (Sac-TMT), given alone or with bevacizumab, can help people with advanced ovarian cancer live longer without their cancer growing. About 900 participants who have finished initial chemotherapy will…

This phase 2 trial is testing an experimental drug called patritumab deruxtecan (HER3-DXd) in 740 people with advanced solid tumors, including melanoma, lung, breast, and other cancers. The drug is given by IV every three weeks. The main goal is to see if the drug shrinks tumors.…

This early-stage study tests a new treatment for people with ovarian cancer that has come back. The therapy uses a patient's own immune cells, which are modified in a lab to recognize and attack a protein (FSHR) found on cancer cells. The main goal is to check the safety of these…

This study tests whether adding the experimental drug IMNN-001 to standard chemotherapy and bevacizumab can better eliminate remaining cancer in people with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer. About 30 participants will be randomly assi…

This phase 3 trial tests whether a new drug, sacituzumab tirumotecan, given with or without bevacizumab, can help people with platinum-sensitive recurrent ovarian cancer live longer without their cancer worsening. About 770 participants who have already completed two rounds of ch…

This phase II trial tests an experimental drug called SYS6041, alone or combined with chemotherapy and other agents, in women whose ovarian cancer has returned. The study evaluates safety, the best dose, and how well the treatments shrink tumors. Participants must have a specific…

This early-phase trial tests whether adding the drug lurbinectedin to two standard chemotherapy drugs (paclitaxel and bevacizumab) can better control platinum-resistant ovarian cancer. About 34 adults with advanced ovarian, fallopian tube, or peritoneal cancer will receive the co…

This phase 2 trial tests whether adding an experimental immune-boosting drug (CDX-1140) to two standard immunotherapies (pembrolizumab and bevacizumab) can shrink tumors in people whose ovarian cancer has returned. About 80 adults with recurrent ovarian, fallopian tube, or perito…

This phase 3 trial tests whether a denser weekly chemotherapy schedule (carboplatin every 3 weeks plus weekly paclitaxel) can help ovarian cancer patients whose tumors are not responding well to standard treatment. The study enrolls 250 adults with advanced ovarian cancer who hav…

This early-stage trial tests an experimental oral drug called APG-2449, alone or combined with another cancer drug, in people with platinum-resistant recurrent ovarian cancer or other advanced solid tumors. The study aims to find safe doses and understand how the drug works in th…

This study tests whether a program of exercise and nutrition counseling helps women with ovarian or endometrial cancer stick with their chemotherapy plan. About 200 women who are about to start chemotherapy will be randomly assigned to either receive weekly coaching sessions on p…

This phase II trial tests the drug abemaciclib in people whose ovarian or endometrial cancer has returned and whose tumors have a specific genetic change (CDK4/6 pathway activation). Abemaciclib is a pill that blocks certain enzymes that cancer cells need to grow. The study will …

This early-phase trial tests a wearable device that creates electric fields (tumor treating fields) combined with either cabozantinib or nab-paclitaxel and atezolizumab in 43 people with advanced solid tumors in the abdomen or chest. The goal is to find the safest dose and see if…

This study tests a drug called relacorilant, taken as a pill, combined with two standard chemotherapy drugs (nab-paclitaxel and bevacizumab) in people with ovarian, fallopian tube, peritoneal, or endometrial cancers. The goal is to see if the combination can slow cancer growth or…

This phase 2 trial investigates whether adding stereotactic body radiotherapy (SBRT) to the PARP inhibitor niraparib can improve control of ovarian cancer that has spread to a limited number of new spots after prior PARP inhibitor therapy. Participants will receive SBRT alone or …

This phase 2 trial is testing a combination of two drugs—vismodegib and atezolizumab—in people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if the combination is safe and can shrink tumor…

This phase 2 trial tests whether combining two oral drugs—ZEN003694 (a BET inhibitor) and talazoparib (a PARP inhibitor)—can shrink tumors in people with recurrent ovarian, fallopian tube, or primary peritoneal cancer. Participants must have already received a PARP inhibitor befo…

This Phase 2 trial tests whether adding the experimental drug ONC201 to standard chemotherapy (paclitaxel) can help women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatments. About 62 participants will receive the combinatio…

This phase 2 trial is testing a drug called lorigerlimab in about 80 people with advanced ovarian or clear cell gynecologic cancers that have stopped responding to platinum chemotherapy. Lorigerlimab is a bispecific antibody designed to activate the immune system against tumors. …

This study tests a new treatment using specially designed immune cells (CAR-NK cells) that target two cancer markers at once. It is for people with ovarian, peritoneal, or fallopian tube cancer that has come back or not responded to standard treatments. The therapy is personalize…

This study is for women with advanced ovarian, fallopian tube, or peritoneal cancer whose tumors did not shrink enough with standard chemotherapy. Researchers are testing a new method called PIPAC, which delivers chemotherapy as a pressurized spray directly into the abdomen, comb…

This early-stage trial tests a new treatment called EB-DUALNK for adults with ovarian cancer that has come back or not responded to standard therapies. The treatment uses specially designed natural killer (NK) cells that target two markers on cancer cells. After a short course of…

This study tests whether adding the experimental drug B013 to standard chemotherapy (paclitaxel) can help people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based treatments. About 90 participants will receive either the comb…

This study tests a technique called acute normovolemic hemodilution (ANH) in 86 women having surgery for advanced ovarian cancer. Before surgery, some blood is removed and stored, then returned during or after the operation. The goal is to see if this reduces the need for donor b…

This study tests a new drug called CapsuleX combined with cisplatin in 40 people whose ovarian cancer no longer responds to platinum-based chemotherapy. The goal is to see if the combination can shrink tumors and how safe it is. Participants must have confirmed ovarian, fallopian…

This study tests a new treatment using specially engineered natural killer (NK) cells to fight ovarian cancer that has come back or not responded to standard therapies. The treatment is personalized: each participant's tumor is checked for three markers, and they receive NK cells…

This early-phase study tests a new treatment for people with ovarian cancer that has returned or is resistant to standard platinum chemotherapy. The treatment uses a patient's own immune cells (T cells), which are trained in a lab to recognize and attack a protein called MUC1 fou…

This early-phase trial is testing the drug talazoparib together with radiation therapy in 24 women whose gynecologic cancer (ovarian, endometrial, cervical, or related cancers) has come back after previous treatment. Talazoparib blocks enzymes that cancer cells need to grow, and …

This phase 2 trial is testing whether a combination of two chemotherapy drugs (paclitaxel or nab-paclitaxel), an immunotherapy (pembrolizumab), and a bladder drug (mirabegron) can shrink tumors in people with ovarian cancer that has come back after initial treatment. About 20 adu…

This study tests a new combination of drugs for people whose ovarian cancer has returned after standard treatment. The drugs include a dual-target immunotherapy (QL1706), chemotherapy, and an oral anti-angiogenic agent (anlotinib). The goal is to see if this combo can shrink tumo…

This study tests if two drugs, senaparib and temozolomide, can shrink tumors in people with a certain type of ovarian cancer that has an ARID1A gene change. About 18 adults with recurrent or persistent clear cell or endometrioid ovarian, fallopian tube, or primary peritoneal canc…

This phase II trial tests whether a custom-made vaccine (FRαDCs) can help prevent or delay cancer from coming back in people with stage III or IV ovarian, fallopian tube, or primary peritoneal cancer. The vaccine is made from a patient's own white blood cells and trained to targe…

This Phase 3 trial is testing whether adding letrozole (a hormone-blocking drug) to standard maintenance therapy can delay cancer recurrence in people with estrogen-receptor-positive ovarian cancer. About 540 participants who have completed initial surgery and chemotherapy will r…

The ORACLE study watches people who have finished treatment for early-stage solid tumors, such as lung, breast, colon, and pancreatic cancers. Researchers want to see if a blood test called Guardant Reveal can find tiny traces of tumor DNA that might signal the cancer is coming b…

This phase I trial is testing a new radioactive tracer called [18F]FTT, which is used with PET/CT scans to find tumor cells in people with solid tumors, including breast, ovarian, and other cancers. The study will enroll 300 participants and aims to see how well the tracer highli…

This study tests a drug called Gleolan that makes ovarian cancer cells glow during surgery. The goal is to help surgeons find and remove tumors they might otherwise miss. About 170 women with suspected or recurrent ovarian cancer will take part. The study lasts about two weeks pe…

This phase 2 trial tests whether cryocompression therapy, alone or combined with the drug cilostazol, can prevent peripheral neuropathy in people receiving paclitaxel for gynecologic cancers. Peripheral neuropathy causes numbness, pain, or tingling in the hands and feet and is a …

This study compares giving cancer treatment at home versus in a clinic for 27 adults with various cancers in the Florida Panhandle. The goal is to see if home treatment is preferred and improves satisfaction, while also checking safety. Participants will receive their usual cance…

This study compares giving cancer treatment at home versus in the clinic for people with advanced cancers. The goal is to see if home treatment reduces stress, financial burden, and improves overall experience. About 220 participants will be randomly assigned to receive their reg…

This study tests a telehealth program called REVITALIZE to see if it can reduce how much fatigue interferes with daily life for adults with advanced ovarian cancer who are taking PARP inhibitors. About 240 participants will either receive the REVITALIZE program or educational mat…

This study tests whether a personalized physical activity program using a wearable device (like a Fitbit) can help people with ovarian or endometrial cancer exercise more and improve their quality of life. About 120 participants will either receive tailored activity goals and fee…

This large screening trial enrolls up to 2,900 people with advanced solid tumors that have spread or not responded to standard treatment. Researchers use genetic tests on tumor samples to find specific mutations, then assign patients to treatment trials testing drug combinations …

This study looks at whether older adults with gynecologic cancer are willing to complete physical and cognitive tests before and after treatment. Researchers will also take small muscle and blood samples to study how cell energy relates to resilience. The goal is to see if this k…

This study looks at whether giving chemotherapy before surgery helps older adults (over 55) with advanced ovarian or endometrial cancer become fitter for their operation. Researchers will measure changes in frailty using a special score from medical records. The goal is to see if…

This study looks at 50 patients with ovarian cancer that has come back quickly (within 6 months). Researchers will track their health and survival to learn more about who responds best to treatment. The goal is to improve how doctors classify and care for these patients.

This study follows 2,000 people who have had ovarian or other solid cancers to learn why some later develop blood cancers like leukemia. Researchers will look at genetic changes in blood cells and treatment history to identify risk factors. No new treatments are being tested—the …

This study looks at 371 people with advanced ovarian, peritoneal, or fallopian tube cancer to find out what factors—like age, tumor type, and genetics—are linked to how long they live. Researchers will collect medical data and blood samples over two years. The goal is to build a …

This study follows 600 Japanese women who carry BRCA1 or BRCA2 gene changes to see how often they develop ovarian, fallopian tube, or peritoneal cancers. Participants are monitored over time, and researchers also check tissue samples from those who choose preventive surgery. The …

This study is testing two genetic tests (Giscar and myChoice) to see if they can identify ovarian cancer patients whose tumors have a specific DNA repair problem (HRD). The goal is to see if these tests can predict which patients will respond well to platinum chemotherapy and may…